
HepG2 cells(black) were incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with ACE2 Antibody(bs-1004R) at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2% BSA in PBS. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green) and isotype control (orange).
ACE2 Polyclonal Antibody
BS-1004R

ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityCanine, Human, Mammals, Mouse, Porcine, Rat, Sheep
TargetACE2
Overview
- SupplierBioss Antibodies
- Product NameACE2 Polyclonal Antibody
- Delivery Days Customer16
- ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
- Applications SupplierWB(1:300-5000), ELISA(1:500-1000), FCM(1:20-100), IHC-P(1:200-400), IHC-F(1:100-500), IF(IHC-P)(1:50-200), IF(IHC-F)(1:50-200), IF(ICC)(1:50-200)
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 ug/ul
- ConjugateUnconjugated
- Gene ID59272
- Target nameACE2
- Target descriptionangiotensin converting enzyme 2
- Target synonymsACEH; ACE-related carboxypeptidase; angiotensin I converting enzyme (peptidyl-dipeptidase A) 2; angiotensin I converting enzyme 2; angiotensin-converting enzyme 2; angiotensin-converting enzyme homolog; angiotensin-converting enzyme-related carboxypeptidase; metalloprotease MPROT15; peptidyl-dipeptidase A; truncated angiotensin converting enzyme 2
- HostRabbit
- IsotypeIgG
- Protein IDQ9BYF1
- Protein NameAngiotensin-converting enzyme 2
- ReactivityCanine, Human, Mammals, Mouse, Porcine, Rat, Sheep
- Storage Instruction-20°C
- UNSPSC12352203
References
- Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue. Liu H et al., 2019, Evid Based Complement Alternat MedRead more